2025
A Perspective on the MARS2 Trial
Lim E, Opitz I, Woodard G, Bueno R, de Perrot M, Flores R, Gill R, Jablons D, Pass H. A Perspective on the MARS2 Trial. Journal Of Thoracic Oncology 2025, 20: 262-272. PMID: 39772349, DOI: 10.1016/j.jtho.2024.12.014.Peer-Reviewed Original ResearchConceptsPleural mesotheliomaPleurectomy decorticationTrial interpretationAssemble individualsAssociated with worse survivalPhase 3 randomized controlled trialsTime of randomizationTeam leadersResectable PMHistological subtypesPreoperative stagingWorse survivalSurgical mortalityConsensus guidelinesTeamAdverse eventsFacilitationChemotherapyPayer's willingnessSurgical communityTrialsSurgeryMesotheliomaQuality assuranceDecortication
2020
Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
Woodard GA, Jablons DM. Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma. Translational Lung Cancer Research 2020, 9: s86-s91. PMID: 32206574, PMCID: PMC7082252, DOI: 10.21037/tlcr.2020.01.08.Peer-Reviewed Original ResearchMalignant pleural mesotheliomaExtrapleural pneumonectomyPleural mesotheliomaSurvival timePleurectomy decorticationSurgical resectionPatient selectionRetrospective single-institution reviewHigh perioperative mortality rateLonger overall survival timeLimited disease burdenMajor surgical resectionRadiation therapy trialsRadical Surgery trialPerioperative mortality rateSingle-institution reviewOverall survival timeShorter survival timeBiased patient selectionLonger survival timeElevated CRPAdvanced diseaseElevated plateletNodal diseaseMPM patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply